The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | Immunotherapeutic approaches to myeloma
David Avigan
• 13 Sep 2019
David Avigan, MD, Harvard Medical School, Boston, MA, gives an update on the immunotherapeutic approaches to multiple myeloma (MM) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA. The most recent efficacy data on the use of CAR T-cells targetting BCMA for MM is discussed as is the use of bispecific antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates and vaccine therapies.
